This company listing is no longer active
Horizon Therapeutics Past Earnings Performance
Past criteria checks 1/6
Key information
50.2%
Earnings growth rate
48.7%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 30.3% |
| Return on equity | 10.3% |
| Net Margin | 14.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Horizon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 3,629 | 521 | 1,543 | 438 |
| 30 Sep 22 | 3,701 | 574 | 1,563 | 508 |
| 30 Jun 22 | 3,813 | 765 | 1,497 | 441 |
| 31 Mar 22 | 3,769 | 862 | 1,482 | 477 |
| 31 Dec 21 | 3,226 | 534 | 1,442 | 345 |
| 30 Sep 21 | 2,957 | 552 | 1,297 | 315 |
| 30 Jun 21 | 2,557 | 518 | 1,190 | 254 |
| 31 Mar 21 | 2,187 | 280 | 1,029 | 195 |
| 31 Dec 20 | 2,200 | 390 | 973 | 129 |
| 30 Sep 20 | 1,819 | 792 | 880 | 122 |
| 30 Jun 20 | 1,518 | 517 | 827 | 161 |
| 31 Mar 20 | 1,376 | 592 | 772 | 109 |
| 31 Dec 19 | 1,300 | 573 | 696 | 103 |
| 30 Sep 19 | 1,292 | 82 | 686 | 94 |
| 30 Jun 19 | 1,282 | 97 | 674 | 91 |
| 31 Mar 19 | 1,264 | 77 | 679 | 87 |
| 31 Dec 18 | 1,208 | -38 | 687 | 83 |
| 30 Sep 18 | 1,126 | -178 | 680 | -65 |
| 30 Jun 18 | 1,073 | -275 | 674 | -68 |
| 31 Mar 18 | 1,059 | -460 | 661 | 70 |
| 31 Dec 17 | 1,056 | -350 | 655 | 66 |
| 30 Sep 17 | 1,092 | -495 | 680 | 218 |
| 30 Jun 17 | 1,029 | -437 | 653 | 213 |
| 31 Mar 17 | 997 | -212 | 626 | 61 |
| 31 Dec 16 | 981 | -166 | 604 | 61 |
| 30 Sep 16 | 915 | -12 | 517 | 49 |
| 30 Jun 16 | 933 | -3 | 496 | 47 |
| 31 Mar 16 | 849 | 14 | 460 | 45 |
Quality Earnings: H1ZN34 has a large one-off loss of $210.3M impacting its last 12 months of financial results to December 31 2022.
Growing Profit Margin: H1ZN34's current net profit margins (14.4%) are lower than last year (16.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: H1ZN34 has become profitable over the past 5 years, growing earnings by 50.2% per year.
Accelerating Growth: H1ZN34's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: H1ZN34 had negative earnings growth (-2.4%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: H1ZN34's Return on Equity (10.3%) is considered low.